Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 7/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22235574 | 0.92 | PARP1 (0.33) | ACHEP2RX7KDM4EALDH1A1PARP1 | |
| SCHEMBL22235669 | 0.77 | PARP1 (0.39) | PARP1 | |
| SCHEMBL24357479 | 0.76 | CNR1 (0.33) | KDM4EALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL24357127 | 0.73 | MAPK8 (0.37) | P2RX7KDM4ETSHRKMT2ASMN1; SMN2 | |
| SCHEMBL22236114 | 0.65 | — | — | |
| SCHEMBL24357008 | 0.64 | MEN1 (0.33) | P2RX7KDM4EALDH1A1PARP1TSHR | |
| SCHEMBL25832157 | 0.62 | MAPK8 (0.42) | KDM4EALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL22236137 | 0.61 | GABRG2 (0.41) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL25832115 | 0.61 | CFTR (0.40) | P2RX7KDM4EALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL30031479 | 0.60 | AADAT (0.35) | KDM4EALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125771-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-04-28 | — | — | US | disclosed |
| CN-113825756-A | Substituted polycyclic carboxylic acids, analogs thereof, and methods of use thereof | 爱彼特生物制药公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3911653-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150366-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125771-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, HDGF | ACHE 4729/4885P2RX7 4130/4885KDM4E 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.